The U.S. Food and Drug Administration accepted a supplemental new drug application for BeiGene’s Bruton’s kinase inhibitor Brukinsa (zanabrutinib) as a potential treatment for Waldenström macroglobulinemia, a type of non-Hodgkin lymphoma.
A late-stage trial failed to show that BeiGene Ltd.’s cancer treatment Brukinsa was superior to Imbruvica, a rival drug from Johnson & Johnson and AbbVie Inc., for treating WM.
